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Abstract 
Cannabidiol (CBD) is being investigated as a treatment for several medical disorders 
but there is uncertainty about its safety. We conducted the first systematic review and 
meta-analysis of the adverse effects of CBD across all medical indications. Double-
blind randomized placebo-controlled clinical trials lasting ≥7 days were included. 12 
trials contributed data from 803 participants to the meta-analysis. Compared to 
placebo, CBD was associated with an increased likelihood of withdrawal for any 
reason (OR 2.61, 95% CI: 1.38 to 4.96) or due to adverse events (OR 2.65, 95% CI: 
1.04 to 6.80), any serious adverse event (OR 2.30, 95% CI: 1.18 to 4.48), serious 
adverse events related to abnormal liver function tests (OR 11.19, 95% CI: 2.09 to 
60.02) or pneumonia (OR 5.37, 95% CI: 1.17 to 24.65), any adverse event (OR 1.55, 
95% CI: 1.03 to 2.33), adverse events due to decreased appetite (OR 3.56, 95% CI: 
1.94 to 6.53), diarrhoea (OR 2.61, 95% CI: 1.46 to 4.67), somnolence (OR 2.23, 95% 
CI: 1.07 to 4.64) and sedation (OR 4.21, 95% CI: 1.18 to 15.01). Associations with 
abnormal liver function tests, somnolence, sedation and pneumonia were limited to 
childhood epilepsy studies, where CBD may have interacted with other medications 
such as clobazam and/or sodium valproate. After excluding studies in childhood 
epilepsy, the only adverse outcome associated with CBD treatment was diarrhoea (OR 
5.03, 95% CI: 1.44 to 17.61). In summary, the available data from clinical trials 
suggest that CBD is well tolerated and has relatively few serious adverse effects, 
however interactions with other medications should be monitored carefully. 
Additional safety data from clinical trials outside of childhood epilepsy syndromes 
and from studies of over-the-counter CBD products are needed to assess whether the 
conclusions drawn from clinical trials can be applied more broadly. 
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Introduction 
Cannabidiol (CBD) has been approved by both the U.S. Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) as an add-on 
treatment for two rare childhood epilepsies: Dravet Syndrome and Lennox-Gastaut 
Syndrome[1]. Recent clinical trials have also examined CBD as a potential treatment 
for diabetes[2], fatty liver disease[3] and schizophrenia[4]. CBD is also available in 
over-the-counter (OTC) preparations which have not been evaluated in clinical 
trials[5]. To date, most clinical trials of CBD have involved 99% pure CBD at doses 
of 300-1500mg/day. OTC preparations typically contain CBD along with other 
cannabinoids, and provide doses of 5-20mg/day. However, some OTC preparations 
reportedly contain much higher or lower quantities of CBD while the market is poorly 
regulated and many products are mislabelled[5]. 
 
The precise molecular mechanism of action of CBD is unclear. Its effects have been 
related to the inhibition of fatty acid amide hydrolase, inhibition of adenosine 
reuptake, agonism of transient receptor potential channels, antagonism of the orphan 
G-protein-coupled receptor GPR55, facilitation of 5-HT1A mediated 
neurotransmission, and inhibition of inflammatory cytokines via action at receptors 
such as peroxisome proliferator-activated receptor-gamma[6–9]. It has a low affinity 
for cannabinoid (CB) receptors, but may act as a negative allosteric modulator at the 
CB1 receptor[10]. 
 
CBD has a reputation for having few adverse effects[11], and this is consistent with 
data from clinical trials[2–4]. Previous reviews of the safety and tolerability of CBD 
did not include meta-analyses [12,13], included data from other cannabinoids[14], or 
were limited to studies in epilepsy[15]. Given the recent approval of CBD by the FDA 
and EMA for childhood epilepsy syndromes, and the wide range of other indications 
for which it is being marketed, a quantitative assessment of its safety and tolerability 
is timely.  The aim of the present study was to address this issue by conducting a 
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systematic review and meta-analysis of the adverse effects of CBD across a range of 
indications.  
 
 
 
Methods 
This systematic review and meta-analysis was prospectively registered on 
PROSPERO (CRD42018111429) and reported according to the PRISMA statement. 
The PRISMA flowchart is shown in Figure 1. 
 
Inclusion & Exclusion Criteria 
We included double-blind randomized controlled clinical trials that reported data on 
withdrawal, serious adverse events, or adverse events from placebo-controlled trials 
of CBD in humans. Studies which were open-label, did not include a placebo 
comparison, were quasi-randomised, or lasted < 7 days were excluded. There were no 
restrictions in relation to participant characteristics or disease indication. 
 
Search Strategy 
We searched Embase, MEDLINE, PsycInfo, and ClinicalTrials.gov. For Embase, 
MEDLINE, PsycINFO we used the keyword search term '(CBD OR cannabidiol) 
AND trial’. For ClinicalTrials.gov we searched for completed studies with the terms 
‘cannabidiol OR CBD’. Each database was searched from its inception until 
31/01/2019. We supplemented this search by reviewing the references of papers and 
systematic reviews identified in the search. 
 
Two reviewers (EC & AG) independently screened the titles and abstracts of all 
articles identified by the search. The full texts of those selected were then reviewed by 
two independent authors (EC & AG). Any disagreements were resolved after 
discussion with a third author (DO).  
 
Data Extraction 
Two authors (from SS, AG, & EC) independently extracted outcome data on 
withdrawals, serious adverse events and adverse events from each study. 
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Systematically recorded data were extracted from studies that had been published in a 
peer-reviewed journal or reported on ClinicalTrials.gov; data from posters, abstracts 
and other informal reports which had not been subject to peer review were excluded. 
If a study reported both treatment-related adverse events and adverse events we 
preferentially extracted adverse events, to reduce the risk of unanticipated adverse 
events being inadvertently disregarded. If two or more reports of the same study 
contained conflicting data, we preferentially used the data reported on 
ClinicalTrials.gov. The two sets of extracted data were then compared and any 
differences were resolved by a third author (EC or DO). Synonymous outcome 
measures were combined (by EC and DO) and are described in Table S2.  
 
Bias Assessment 
Each study was assessed for bias using the Cochrane Risk of Bias Tool, which 
includes the following criteria: random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data, selective reporting, other bias[16]. Each criterion was rated as being at 
high, low, or unclear risk of bias by two independent raters (AG and SS). 
Disagreements were resolved after discussion with a third author (EC or DO). 
 
Statistical analysis 
We conducted a pairwise meta-analysis of all outcomes for CBD vs. placebo where 
more than 8 events were recorded across both arms of all studies. As all outcomes 
were dichotomous, we calculated odds ratios (OR) with 95% confidence intervals 
using the Mantel-Haenszel method, where an OR greater than 1 indicates an increased 
likelihood of the event when treated with CBD compared to placebo and an OR below 
1 indicates a reduced likelihood.  
 
To convert mg/kg into a comparable daily dose we multiplied doses by 70kg. 
Subgroup analyses of epilepsy studies and non-epilepsy studies were completed. 
Random-effects models were used to control for heterogeneity and we completed 
meta-regression analyses of CBD dosage. In such cases, data from the placebo arm 
were divided by the number of CBD arms contributing data to the meta-regression. 
Risk of publication bias was tested with the Egger regression intercept method and 
visual inspection of funnel plots. The significance level was set to p<0.05 (two-
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tailed).  Pairwise analyses were conducted using Review Manager Version 5.3. Meta-
regression analyses and publication bias analyses were conducted using 
Comprehensive Meta-Analysis Version 3. 
 
Results 
Identification of Studies 
The systematic search identified 28 independent randomized double-blind placebo-
controlled clinical trials (Figure 1), comprising data from a total of 1589 participants. 
Ten studies were excluded from further analysis because they were only reported in 
abstracts, posters, or secondary descriptions from the grey literature. A further 5 were 
excluded because they did not report data on withdrawal or adverse events in a 
systematic way. The remaining 13 trials included a total of 822 participants and 
reported 266 different adverse outcomes, of which 33 provided sufficient data for 
meta-analysis (i.e. at least 8 events across arms across studies per outcome) (Table 1). 
One study [3] met all the inclusion criteria but none of the events it reported occurred 
in outcomes relevant to the meta-analysis. It contributed data to estimates of event 
rates but did not contribute data to the calculation of odds ratios. This meant that 12 
trials using data from 803 participants contributed data to the meta-analysis. The 
studies which were not included are described in Table S1.  
 
Of the 13 studies included in the systematic review, 5 involved patients with epilepsy 
and 2 involved patients with schizophrenia. The remaining 6 studies involved subjects 
with problematic cannabis use, Huntington’s disease, type II diabetes, non-alcoholic 
fatty liver disease, Crohn’s disease and healthy volunteers. The duration of treatment 
ranged from 1 to 14 weeks, and the dose of oral CBD ranged from 200mg to 3000mg 
per day. The mean oral dose used was 1132mg/day and the median dose was 
1200mg/day. One study used sublingual CBD at a dose of 20mg/day.  In epilepsy 
studies the mean oral dose was 1214mg/day; in non-epilepsy studies the mean oral 
dose was 918mg/day. All trials are believed to have used pure, pharmaceutical-grade 
CBD, with minimal other cannabinoids. 
 
Meta-Analysis 
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We report on our primary outcome measures below, together with any secondary 
outcome which achieved statistical significance (p<0.05) (Figure 2) and subgroup 
analyses of epilepsy and non-epilepsy studies (Figure 3 and Figure 4).  Non-
significant secondary outcomes are described in Table S4. 
 
Withdrawal 
Across all doses, there were more withdrawals due to any reason (OR 2.61, 95% CI: 
1.38 to 4.96) in CBD groups compared to placebo. The likelihood of withdrawal 
appeared to depend on the dose of CBD. At high doses (1400-3000mg) 12.9% 
(35/272) of participants withdrew, compared to 8.8% (14/160) at medium doses (600-
1000mg), and only 4.3% (2/46) at low doses (20-400mg), a similar rate to placebo 
(3.5% [12/344]). Meta-regressions indicated that there was a trend for an effect of 
CBD dose on withdrawal (β = 0.0014; p = 0.077). Withdrawal due to adverse events 
was also higher in CBD groups compared to placebo (OR 2.65, 95% CI: 1.04 to 6.80), 
although there was no significant correlation with CBD dose in the meta-regression (β 
= 0.0014; p = 0.274). 
 
In studies of patients with rare epilepsy syndromes there was an increased odds of 
withdrawal due to any reason (OR 3.71, 95% CI: 1.60 to 8.64), and withdrawal due to 
adverse events (OR 3.91, 95% CI: 1.32 to 11.62). However, in non-epilepsy studies 
withdrawal due to any reason (OR 1.62, 95% CI: 0.61 to 4.34) or adverse events (OR 
0.84, 95% CI: 0.13 to 5.46) was no more common than with placebo. 
 
Serious Adverse Events 
There were 61 serious adverse events in 415 participants in the CBD arms (14.7%), 
compared to 18 among 295 participants in the placebo arms (6.1%), an OR of 2.30 
(95% CI: 1.18 to 4.48). The result of the dosage meta-regression was not significant 
(p=0.169). In epilepsy studies the odds ratio was 2.70 (95% CI: 1.47 to 4.94), in non-
epilepsy studies it was 0.34 (95% CI: 0.03 to 3.38). This results from serious adverse 
events associated with CBD treatment being limited to studies in children with 
epilepsy. 
 
There was an increased OR for pneumonia (OR 5.37, 95% CI: 1.17 to 24.65). This 
reflected 14 cases of pneumonia recorded as a serious adverse event in patients treated 
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with CBD, compared to only 1 in placebo arms. An additional 2 cases of pneumonia 
were recorded as (non-serious) adverse events in patients treated with CBD in another 
study[17]. However, pneumonia was only reported in studies of children with 
epilepsy. 
 
There was an increased OR for abnormal liver function tests (OR 11.19, 95%CI: 2.09 
to 60.02), with all 21 events occurring in the CBD groups compared to no events in 
patients treated with placebo. These differences were only evident in studies involving 
childhood epilepsy, and most of the events (19 of 21) occurred when CBD was given 
at high doses (20mg/kg or more). Each of the three trials contributing data to this 
outcome used a cut-off of >3 times the upper limit of normal for transaminase 
increases.  
 
Adverse Events 
The OR for experiencing any adverse event with CBD compared to placebo was 1.55 
(95% CI: 1.03 to 2.33). 67.6% of CBD-treated participants reported an adverse event, 
compared to 54.5% of those treated with placebo. Here, the results of dosage meta-
regression were highly significant (β = 0.0013, p = 0.0023): the likelihood of an 
adverse event was strongly related to the dose of CBD. The likelihood of adverse 
events also differed according to the clinical group being treated (Chi2 = 4.17; p = 
0.04). In the five studies involving children with epilepsy, 67.8% of those given CBD 
had adverse events, compared to 51.5% on placebo (OR 1.92, 95% CI: 1.33 to 2.78), 
whereas in the five non-epilepsy studies the rates were similar: 67.0% and 62.2% 
respectively (OR 0.85, 95% CI: 0.42 to 1.70). 
 
CBD was also associated with a greater OR for decreased appetite (OR 3.56, 95% CI: 
1.94 to 6.53), diarrhoea (OR 2.61, 95% CI: 1.46 to 4.67), sedation (OR 4.21, 95% CI: 
1.18 to 15.01) and somnolence (OR 2.23, 95% CI: 1.07 to 4.64). In epilepsy studies 
CBD was associated with decreased appetite (OR 4.12, 95% CI: 2.16 to 7.85), 
diarrhoea (OR 2.18, 95% CI: 1.09 to 4.33) and somnolence (OR 3.00, 95% CI: 1.60 to 
5.61). Sedation (OR 4.10, 95% CI: 0.89 to 18.91) was not statistically different from 
placebo (p=0.07). In non-epilepsy studies the only event that was more frequent with 
CBD was diarrhoea (OR 5.03, 95% CI: 1.44 to 17.61). 
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Other outcomes 
All other outcomes were non-significant (p>0.05; Table S4).  
 
Risk of bias 
Ten studies were rated as having a low risk of bias[2–4,17–23], one was rated as 
having an unclear risk of bias [24], and two studies were rated as having a high risk, 
due to selective outcome reporting [25,26]. Results of the risk of bias assessment are 
described in Table S3.  
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Discussion 
To our knowledge, this is the first systematic review and meta-analysis of the adverse 
effects and tolerability of CBD across all indications. We identified a total of 28 trials, 
of which 13 met inclusion criteria and 12 provided suitable data for meta-analysis 
from a total of 803 participants. Our main findings were that although CBD was 
associated with a greater likelihood of adverse events and study withdrawal, this was 
almost entirely specific to studies in rare forms of epilepsy. These differed from the 
others we examined, in that they involved relatively high doses of CBD in children, 
many of whom were also being treated with other anti-epileptic medications.  
 
CBD is a potent inhibitor of the CYP450 enzymes, CYP3A4 and CYP2C19. These 
hepatic enzymes metabolise clobazam and sodium valproate, which were prescribed 
in over half of the patients in the three main epilepsy studies included in the meta-
analysis[17,18,27]. Inhibition of CYP2C19 can increase the levels of clobazam’s 
metabolite, N-desmethylclobazam, by two to seven-fold, which has a significant 
sedative effect[28]. In a recent experimental study, even very high acute doses of 
CBD (1.5g & 4.5g orally) had limited effects on alertness, suggesting that CBD alone 
is not usually sedative[29]. Increased N-desmethylclobazam levels could also account 
for the increased odds of pneumonia in epileptic patients taking CBD, as this 
increases the risk of sedation, respiratory depression and aspiration[30]. Again, these 
events only occurred in patients prescribed high doses of CBD (10-20mg/kg/day). It is 
less clear if CBD interacts with clobazam at lower doses, although it has been 
reported that CBD inhibits CYP2C19 at doses of 5mg/kg[31], and therefore has the 
potential to interact with a wide range of other commonly prescribed medications 
even at low-medium doses. The majority of cases with abnormal liver function tests 
were in children with epilepsy who were also being treated with sodium valproate. 
The exact mechanism of this interaction is not fully understood. Co-administration of 
CBD and valproate does not significantly alter their plasma levels or that of their 
metabolites[32]. However, the metabolite 7-COOH-CBD, valproate and its metabolite 
4-ene-valproic acid may affect hepatic mitochondrial function[33]. 
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An increased incidence of diarrhoea in CBD-treated individuals is consistent with 
data from a small experimental study, which found that single doses of CBD, 1.5g and 
4.5g, produced diarrhoea in 10% and 20% of participants respectively[29]. This may 
reflect the endocannabinoid system’s role in the regulation of gastrointestinal 
motility[34]. CBD treatment was also associated with reduced appetite in the epilepsy 
studies. The endocannabinoid system contributes to the regulation of food intake and 
moderates the hedonic effect of food consumption[35]. Previous studies have 
suggested that CBD in cannabis may reduce the appetitive effects of food stimuli[36], 
but its molecular mechanism of action in this context remains unclear. Rimonabant, a 
selective inverse agonist at the CB1 receptor, reduces appetite and weight and was 
approved as a treatment for obesity before being withdrawn because of adverse 
psychiatric side effects[37]. Dronabinol, a synthetic form of THC, and a partial 
agonist at CB receptors, has been used as a treatment for anorexia and cachexia in 
HIV and cancer[38,39]. In the trials identified by our systematic search, weight was 
monitored too infrequently to be evaluated. 
 
Strengths of the present study include its pre-registered protocol, comprehensive 
systematic search strategy, and its timeliness as the first meta-analysis of the safety 
and tolerability of CBD across all indications.  The overall quality of studies included 
was high and it is unlikely that a significant amount of bias was introduced. 
Publication bias is also unlikely to have inflated summary ORs, as our target 
outcomes were not the primary outcome measure, nor the desired outcomes for the 
studies we examined. Many studies in our systematic review were excluded from the 
meta-analysis because they did not report adverse events systematically or had not 
been peer-reviewed. The meta-analysis therefore only contained data from 803 
participants, reducing its power to identify uncommon adverse events. We included 
studies across a range of treatment indications which aids generalizability to different 
patient groups in clinical practice. However, most (69%) of the participants in our 
meta-analysis had childhood epilepsy. This is an important consideration, as these 
studies involved children rather than adults, relatively high doses of CBD, and the 
patients were often taking other epilepsy medications which can interact with CBD. 
Although we were able to stratify our analysis to investigate differences between the 
studies on epilepsy and on other indications, there is a need for further studies that 
include a broader range of patient groups and indications.  
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A key consideration in interpreting our findings is that the doses of CBD used in the 
trials we studied were relatively high (median dose 1200mg/day; mean dose 1132mg): 
only 46 of 822 participants received doses at or below 400mg/day or 
5mg/kg/day[2,3,21,25]. The doses of CBD provided by health and food supplements 
are typically much lower (5-20mg/day[5]), so the incidence of adverse events is likely 
to be lower. However, this has yet to be demonstrated. This issue requires more 
research, as the commercial CBD market is poorly regulated. At present, some OTC 
products are poorly labelled, others do not contain purified CBD, and many contain 
other cannabinoids or contaminants in addition to CBD [40][41]. 
 
Conclusions 
CBD is well tolerated and has few adverse effects. However, its ability to inhibit the 
hepatic metabolism of other medications (such as clobazam and sodium valproate) 
has the potential to cause adverse effects. This is demonstrated by the increased rates 
of adverse events, serious adverse events and withdrawals in trials for childhood 
epilepsy syndromes but not other indications. Additional safety data from clinical 
trials outside of childhood epilepsy syndromes and from studies of OTC CBD 
products would be beneficial. 
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Figure 1 Flowchart describing the systematic search strategy 
